Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | CHRYSALIS trial update in NSCLC

Byoung Chul Cho • 21 Sep 2020
ESMO 2020
Non-Small Cell Lung Cancer Amivantamab Antibodies Lazertinib
CHRYSALIS

Byoung Chul Cho, MD, PhD, Yonsei Cancer Center, Seoul, Korea, discusses the Phase I CHRYSALIS study (NCT02609776), investigating the use of amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody, in combination with lazertinib, a third-generation tyrosine kinase inhibitor (TKI), in advanced EGFR non-small-cell lung cancer (NSCLC). The study showed encouraging preliminary activity in patients with osimertinib-relapsed disease. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Byoung Chul Cho

Elisrasib shows durable activity in pretreated KRAS G12C-mutant NSCLC
3:30
Elisrasib shows durable activity in pretreated KRAS G12C-mutant NSCLC
Byoung Chul Cho • 27 Apr 2026
COCOON: dermatologic management with amivantamab & lazertinib
3:34
COCOON: dermatologic management with amivantamab & lazertinib
Byoung Chul Cho • 6 Sep 2025
TRIDENT-1: long-term results of repotrectinib in ROS+ NSCLC
2:18
TRIDENT-1: long-term results of repotrectinib in ROS+ NSCLC
Byoung Chul Cho • 7 Sep 2025
The future of amivantamab and lazertinib in EGFR-mutant NSCLC
0:47
The future of amivantamab and lazertinib in EGFR-mutant NSCLC
Byoung Chul Cho • 20 Oct 2023

Related Videos

Zidesamtinib in TKI-naïve patients with ROS1+ NSCLC: insights from the ARROS-1 trial
4:59
Zidesamtinib in TKI-naïve patients with ROS1+ NSCLC: insights from the ARROS-1 trial
Alexander Drilon • 7 Oct 2026
WCLC 2026 highlights: T-DXd in HER2-mutant NSCLC and advances in targeted therapies
0:59
WCLC 2026 highlights: T-DXd in HER2-mutant NSCLC and advances in targeted therapies
Alexander Drilon • 7 Oct 2026
Activity of zidesamtinib for ROS1+ NSCLC in TKI-naïve and pre-treated patients
0:52
Activity of zidesamtinib for ROS1+ NSCLC in TKI-naïve and pre-treated patients
Alexander Drilon • 7 Oct 2026
Updated PALOMA-2 results: subcutaneous amivantamab + lazertinib in NSCLC
1:10
Updated PALOMA-2 results: subcutaneous amivantamab + lazertinib in NSCLC
Misako Nagasaka • 14 Sep 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals